Analysis Of The Efficacy Of Tadalafil Combined With Growth Hormone In Treating Refractory Erectile Dysfunction

Objective:To explore the safety and clinical efficacy of small-dose tadalafil combined with recombinant human growth hormone in refractory erectile dysfunction.Methods:Thirty-six patients with refractory erectile dysfunction,aged from 25 to 65 years,were collected from urology and andrology outpatients of our hospital from June2022 to February 2023.Patients were randomly divided into control group and growth hormone group using SPSS random number generator method,in which the control group was given tadalafil tablets(5 mg,orally,once a night),and the growth hormone group was combined with recombinant human growth hormone(2 u,subcutaneous injection before bedtime,once every Monday and Thursday)on the basis of the control group.The International index of erectile function-5(IIEF-5),the Erection hardness score(EHS),and questions 2(SEP2)and 3(SEP3)in the Sexual Encounter Profile(SEP)were recorded before medication,1 month after medication,and 3 months after medication.At the same time,the changes of liver and kidney function,blood glucose,blood lipids,testosterone and IGF-1 before and 3 months after medication were monitored,PSA was monitored for patients aged ≥50 years,adverse reactions occurred during treatment were recorded and statistically analyzed the above data.Results:A total of 36 patients were enrolled in the study and followed up,and after 3months of treatment,the IIEF-5 scores of the control group and the growth hormone group ranged from 7.72±1.45 points,7.94±1.47 points to 12.11±2.42 points,15.06±2.82 points,respectively,and there were significant differences between the two groups after treatment(P<0.05),and the significance of the growth hormone group was higher than that of the control group(P<0.05).After three months of treatment,the total effective rates of the control group and the growth hormone group were 27.8% and 66.7%,respectively,and the difference between the two groups was statistically significant(P<0.05).After 3 months of treatment,EHS in the two groups was 2.17±0.38 and 2.50±0.51,respectively,which was significant compared with the previous difference(P<0.05),and the growth hormone group was significantly higher than the control group(P<0.05).Before treatment,the SEP2/3 of the two groups answered "yes" was 0%.After 1 month and 3 months of treatment,the SEP2/3 of the control group was 11.1%/0%,22.2%/5.6%,and the SEP2/3 of the growth hormone group was 16.7%/22.2%,61.1%/38.9%,respectively.There were significant differences in SEP2/3 between the two groups after 3 months of treatment(P<0.05).There was no significant difference in blood indexes except IGF-1 in the growth hormone group after treatment(P<0.05).During treatment,there was no significant difference between the adverse reaction rate of the control group(11.1%)and the growth hormone group(22.2%)(P>0.05).Conclusions:1.Low-dose tadalafil tablets in combination with recombinant human growth hormone significantly improves symptoms of refractory erectile dysfunction without increasing the incidence of adverse effects.2.IGF-1 may be the main mediator of recombinant human growth hormone acting in vivo.3.Recombinant human growth hormone may be able to improve sleep quality and increase energy by regulating mood.